The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding
Sarah Hanigan, Jessica Das, Kristen Pogue, Geoffrey D. Barnes, Michael P. Dorsch
Topics & Concepts
MedicineApixabanRivaroxabanInternal medicineRetrospective cohort studyHazard ratioAtrial fibrillationPropensity score matchingStroke (engine)Confidence intervalWarfarinMechanical engineeringEngineeringAtrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAntiplatelet Therapy and Cardiovascular Diseases